6.10
+0.66%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Emergent BioSolutions
From its filings with the US Securities and Exchange Commission
Emergent BioSolutions is based in Gaithersburg, Maryland and is incorporated in Delaware. Its shares trade on NYSE under the ticker EBS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $742.9m and net income of $52.6m. At that date it held total assets of $1.32bn and shareholders' equity of $522.6m.
Our revenues are derived from a combination of the sale and procurement of our product/product candidate portfolio (described below), the provision of our bioservices to external customers, and non-dilutive contract and grant funding for research and development (“R&D”) projects from various third-party sources.
As of December 31, 2025, the Company has a portfolio of 11 products focused on addressing global public health threats like smallpox, mpox, anthrax, Ebola and opioid overdose emergencies. The revenues generated by the products comprise a substantial portion of our revenue. We structure our business with a focus on markets and customers. As such, the key components of the business structure include the following four product and service categories: Commercial products, consisting of NARCAN® Nasal Spray and KLOXXADO®, Anthrax – Medical Countermeasures (“MCM”) Products, Smallpox - MCM products, and Emergent Bioservices (CDMO) (“Bioservices”).
Additionally, we have a centralized R&D organization and an enterprise-wide governance approach to managing our portfolio of R&D projects.
Quoted from its 10-K, filed 27 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Nov 2006
- Employees
- 900
- Website
- emergentbiosolutions.com ↗
- Head office
- 300 PROFESSIONAL DR, GAITHERSBURG, MD, 20879
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Dr. Zsolt HarsanyiIndependent Chairman of the Board$420,000
- Mr. Joseph PapaPresident, Chief Executive Officer, Director, since 2024$5.9m
- Mr. Richard LindahlChief Financial Officer, Executive Vice President, Treasurer$2.3m
- Ms. Coleen GlessnerExecutive Vice President - Quality and Ethics and Compliance$2.1m
- Ms. Jessica PerlSenior Vice President, General Counsel, Corporate Secretary
- Mr. William HartzelSenior Vice President - Manufacturing and Bioservices$1.7m
- Mr. Paul WilliamsSenior Vice President - Products Business$1.7m
- Dr. Simon LowryChief Medical Officer, Head of Research and Development
- Ms. Sujata DayalIndependent Director$275,000
- Mr. Donald DegolyerIndependent Director$265,000
- Mr. Neal FowlerIndependent Director$270,000
- Mr. Keith KatkinIndependent Director$285,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 52
- Environment
- 36
- Social
- 65
- Governance
- 54
- Direct emissions (scope 1)
- 12,800 t
- Energy emissions (scope 2)
- 14,812 t
- Women in the workforce
- 54%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Emergent BioSolutions Inc has several strengths that contribute to their success:
- Despite its strengths, Emergent BioSolutions Inc also faces certain weaknesses:
- Emergent BioSolutions Inc can leverage the following opportunities to further grow its business:
- Emergent BioSolutions Inc faces certain threats that could impact its operations:
Weaknesses
- Despite its strengths, Emergent BioSolutions Inc also faces certain weaknesses:
- Emergent BioSolutions Inc can leverage the following opportunities to further grow its business:
- Emergent BioSolutions Inc faces certain threats that could impact its operations:
Opportunities
- Emergent BioSolutions Inc can leverage the following opportunities to further grow its business:
- Emergent BioSolutions Inc faces certain threats that could impact its operations:
Threats
- Emergent BioSolutions Inc faces certain threats that could impact its operations:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.